Germany
Japan
United Kingdom
China
Active filters
Clonalities
- Monoclonal
Filter by
Target Symbol
- VSNL1 (272)
- ALK (269)
- KLK8 (253)
- CD4 (244)
- PDCD1 (228)
- ERBB2 (216)
- CD5 (215)
- MAP2K1 (214)
- TP53 (207)
- CDKN2A (183)
- NME1 (170)
- PGR (168)
- GFAP (166)
- ABCB1 (163)
- JUN (157)
- MKI67 (156)
- ERCC1 (153)
- MAP2K3 (151)
- GLI1 (149)
- EGFR (148)
- KRT19 (142)
- PECAM1 (140)
- UCHL1 (139)
- TG (137)
- IL6 (136)
- CD274 (135)
- CD68 (131)
- CTAG1B (131)
- CTNNB1 (130)
- GADD45G (130)
- LIPG (130)
- CD40 (129)
- HAVCR2 (129)
- NBN (126)
- OTC (125)
- PTPRC (125)
- VIM (124)
- MSMB (123)
- CD99 (122)
- S PROTEIN (122)
- LCN2 (113)
- PCNA (113)
- CD80 (112)
- NKX3-1 (112)
- CFI (111)
- PIK3C2A (111)
- AFP (108)
- ADIPOQ (107)
- MDM2 (107)
- NUMB (106)
- IL1RL1 (105)
- EPCAM (104)
- LGALS3 (103)
- CTLA4 (102)
- N PROTEIN (102)
- VWF (102)
- CD8A (101)
- CD44 (99)
- MAPK13 (98)
- MLANA (98)
- CD47 (97)
- CD63 (97)
- IL17A (97)
- L1CAM (96)
- MS4A1 (96)
- TOP2A (96)
- KRT20 (95)
- UBE2E3 (95)
- APP (91)
- SENP2 (90)
- TNFRSF8 (90)
- NKX2-1 (89)
- BCL2 (88)
- BTLA (87)
- CD33 (87)
- F13A1 (87)
- PNMT (87)
- S100A8/A9 (87)
- CD19 (86)
- TYMS (86)
- KIT (85)
- D-DIMER (83)
- CD27 (82)
- MLH1 (82)
- MPO (82)
- BRAF (81)
- PDCD1LG2 (81)
- SAA1 (81)
- MDM4 (80)
- MIEN1 (80)
- CD86 (79)
- CHGA (78)
- TIGIT (78)
- ALDH1L1 (75)
- NCAM1 (75)
- TACC2 (75)
- CD163 (74)
- LGR5 (74)
- NEFL (74)
- FGF21 (73)
Reactivities
- Human (70372)
- Mouse (39654)
- Rat (37783)
- Monkey (4563)
- Dog (3955)
- SARS-CoV-2 (257)
- Bovine (122)
- Rabbit (88)
- Hamster (85)
- Porcine (81)
- Canine (73)
- Chicken (65)
- Primate (57)
- HIV (52)
- Pig (42)
- Sheep (39)
- Xenopus (29)
- Zebrafish (29)
- Guinea Pig (27)
- Virus (23)
- Drosophila (21)
- Chimpanzee (18)
- Escherichia coli (18)
- Feline (16)
- Mammalian (16)
- Cow (13)
- Frog (13)
- Goat (12)
- Yeast (12)
- C-term DDK (10)
- Fish (10)
- Macaque (10)
- Adenovirus 2 (9)
- All Species (9)
- Streptococcus Pyogenes (9)
- Vertebrates (9)
- Equine (8)
- SARS-CoV (8)
- Saccharomyces cerevisiae (8)
- Adenovirus 5 (7)
- Adenovirus 8 (6)
- Baboon (6)
- C. elegans (6)
- Adenovirus (5)
- Avian (5)
- Horse (5)
- Opossum (5)
- Cynomolgus (4)
- Ferret (4)
- Fruit fly (4)
- Insect (4)
- Rhesus Monkey (4)
- Amphibian (3)
- Beluga (3)
- Marmoset (3)
- Plant (3)
- Respiratory Syncytial Virus (3)
- Adenovirus 9 (2)
- Bacteria (2)
- Dengue virus (2)
- Dictyostelium (2)
- Drosophila melanogaster (2)
- N-term and C-term DDK (2)
- Tomato (2)
- West Nile Virus (2)
- Yellow Fever Virus (2)
- Bacillus Antracis (1)
- Broad (1)
- Carp (1)
- Chlamydomonas (1)
- Fungi (1)
- Helicobacter pylori (1)
- Salmonella Typhimurium (1)
- Spinach (1)
- Squirrel (1)
- Staphylococcus aureus (1)
- Trichinella spiralis (1)
- White Fly (1)
Applications
- WB (70086)
- IHC (35526)
- FC (23226)
- IF (21321)
- ELISA (8340)
- IP (4230)
- LMNX (1108)
- FN (656)
- 10k-ChIP (435)
- Assay (201)
- NEUT (178)
- R (161)
- Bl (92)
- CT (76)
- Protein Purification (64)
- ICC (53)
- LF (35)
- SISCAPA (35)
- E (34)
- ChIP (33)
- EM (27)
- AGG (25)
- Neutralize (25)
- Inhib (24)
- ID (11)
- RNAi (11)
- ISH (6)
- P (6)
- Dot (5)
- Elispot (5)
- PLA (5)
- C (4)
- EMSA (4)
- ICC/IF (4)
- MC (3)
- SB (3)
- CLIA (2)
- EIA (2)
- Func (2)
- Labeling (2)
- H (1)
- IA (1)
Antibody Hosts
Isotypes
- IgG1 (53888)
- IgG2a (13778)
- IgG2b (11640)
- IgG (1876)
- IgG1, kappa (587)
- IgM (488)
- IgG, kappa (382)
- IgG3 (368)
- IgG2a, kappa (178)
- IgG2 (117)
- IgG2b, kappa (112)
- IgG2c (52)
- IgG1, lambda (36)
- Fab fragment, kappa (25)
- IgG3, kappa (23)
- IgM, kappa (22)
- IgA (20)
- IgG4 (13)
- IgG2a, lambda (11)
- IgG1-Fc Fusion (8)
- cocktail (8)
- IgG2, kappa (6)
- IgG2b, lambda (6)
- Fab fragment, lambda (4)
- IgA-Fc Fusion (4)
- IgE (4)
- IgG-Fc Fusion (4)
- IgM-Fc Fusion (4)
- Ig (2)
- IgD (2)
- IgG1/IgG2a (2)
- IgG1/IgG2b (2)
- scFv (2)
- F(ab)2, kappa (1)
- IgA, kappa (1)
- IgG fraction (1)
- IgG/IgM (1)
- IgG1/IgK (1)
- IgG1/IgM (1)
- IgG12b (1)
- IgG2, alpha (1)
- IgG3/IgG1 (1)
Conjugates
- Unconjugated (46843)
- Biotin (13509)
- HRP (12504)
- FITC (1052)
- PE (818)
- APC (177)
- Alexa Fluor 488 (59)
- Alexa Fluor 647 (54)
- Alexa Fluor 546 (52)
- PerCP (38)
- AP (32)
- Magnetic Beads (31)
- His Tag (30)
- PE-Cy7 (23)
- Cy5 (18)
- APC-Cy7 (15)
- TRITC (12)
- APC-Cy5.5 (10)
- Agarose (7)
- DyLight 488 (7)
- PE-Cy5.5 (7)
- PE-TXRD (7)
- PE-DL594 (4)
- BIMA (3)
- FLMA (3)
- PerCP-Cy5.5 (3)
- Sepharose (3)
- DyLight 550 (2)
- DyLight 594 (2)
- TAMRA (2)
- Agarose Beads (1)
- DyLight 633 (1)
- PE-Cy5 (1)
- Texas Red (1)
Carrier-free
Knockout (KO) Validation
Modifications
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques. (94)
- This is a chimeric antibody created as part of a panel offering antibodies of the same specificity in different formats (species, isotype, subtype and modified versions) for use as isotype controls. (60)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2a format, for improved compatibility with existing reagents, assays and techniques. (36)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (27)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (23)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG1 format, for improved compatibility with existing reagents, assays and techniques. (20)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (18)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human Fab format, for improved compatibility with existing reagents, assays and techniques. (17)
- Phospho-specific (16)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (15)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (15)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2b format, for improved compatibility with existing reagents, assays and techniques. (14)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (14)
- This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. (12)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (8)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2a format, for improved compatibility with existing reagents, assays and techniques. (8)
- This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (8)
- This full-length, chimeric rabbit antibody was made using the variable domain sequences of the original Mouse scFv format, for improved compatibility with existing reagents, assays and techniques. (7)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG format, for improved compatibility with existing reagents, assays and techniques. (6)
- This full-length, chimeric rabbit antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. (6)
- This full-length, reformatted mouse antibody was made using the variable domain sequences of the original Mouse scFv format, for improved compatibility with existing reagents, assays and techniques. (6)
- This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (6)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG format, for improved compatibility with existing reagents, assays and techniques. (6)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric mouse antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG3 format, for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgM format, for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original rat IgG2a format, for improved compatibility with existing reagents, assays and techniques. (4)
- This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. (4)
- Modification (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG2 format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgM format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original human scFv format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2b format, for improved compatibility with existing reagents, assays and techniques. (3)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (3)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric hamster (Armenian) antibody was made using the variable domain sequences of the original Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric mouse antibody was made using the variable domain sequences of the original Hamster IgG1 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG1 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG format, for improved compatibility with existing reagents, assays and techniques. (2)
- This constant region of this antibody has been modified to bind to Protein A, allowing highly-specific purification of this antibody by Protein A-affinity column. (2)
- This full-length, chimeric mouse antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. (2)
- This reformatted rat antibody was made using the variable domain sequences of the original Rat IgG format, for improved compatibility with existing reagents, assays and techniques. (2)
- This reformatted rat antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgM format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric murine antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Armenian Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Armenian Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse scFv antibody fragment format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG3 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (1)
- This full-length, chimeric mouse antibody was made using the variable domain sequences of the original Chicken scFv format, for improved compatibility with existing reagents, assays and techniques. (1)
- This full-length, chimeric rabbit antibody was made using the variable domain sequences of the original Chicken scFv format, for improved compatibility with existing reagents, assays and techniques. (1)
- This is a chimeric antibody created to reduce immunogenicity during in vivo applications. (1)
- This is a chimeric human antibody, based on the original mouse IgG2a format, created for improved compatibility with existing reagents, assays and techniques. (1)
- This is a chimeric mouse antibody, based on the original hamster IgG format, created for improved compatibility with existing reagents, assays and techniques. (1)
- This is a chimeric mouse antibody, based on the original rat IgG2b format, created for improved compatibility with existing reagents, assays and techniques. (1)
- This is a chimeric recombinant Fab fragment created as part of a panel offering antibodies of the same specificity in different formats (species, isotype, subtype and modified versions) for use as isotype controls. (1)
- This is a recombinant chimeric Fab fragment created as part of a panel offering antibodies of the same specificity in different formats (species, isotype, subtype and modified versions) for use as isotype controls. (1)
- This is a reformatted human IgG1 antibody based on the therapeutic Fab fragment. NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (1)
- This is a reformatted mouse IgG1 antibody, based on the original mouse IgG2a format, created for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted antibody was made using the variable domain sequences of the original mouse IgG2b format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted antibody was made using the variable domain sequences of the original rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG3 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse scFv antibody fragment format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original mouse scFv format for improved compatibility with existing reagents, assays and techniques. (1)
Assay Types
Assay Platforms
Families
- Druggable Genome (40612)
- Transmembrane (13677)
- Transcription Factors (11035)
- Secreted Protein (6998)
- ES Cell Differentiation/IPS (5946)
- Protein Kinase (4464)
- Protease (3214)
- Stem cell - Pluripotency (2609)
- Adult stem cells (1524)
- Embryonic stem cells (953)
- Nuclear Hormone Receptor (949)
- Phosphatase (738)
- Cancer stem cells (665)
- Induced pluripotent stem cells (503)
- Stem cell relevant signaling - DSL/Notch pathway (427)
- Stem cell relevant signaling - JAK/STAT signaling pathway (364)
- P450 (309)
- Ion Channels: Other (304)
- GPCR (210)
- Stem cell relevant signaling - TGFb/BMP signaling pathway (173)
- Stem cell relevant signaling - Wnt Signaling pathway (75)
- Ion Channels: Potassium (50)
- Ion Channels: Transient receptor potential (37)
- Ion Channels: Cys-loop Receptors (28)
- Ion Channels: Sodium (9)
- Ion Channels: Calcium (4)
- Ion Channels: Glutamate Receptors (2)
- Ion Channels: Cyclic nucleotide gated (1)
Pathways
- Metabolic pathways (6438)
- Pathways in cancer (5108)
- MAPK signaling pathway (3184)
- Focal adhesion (2603)
- Cell adhesion molecules (CAMs) (2538)
- Cytokine-cytokine receptor interaction (2469)
- Prostate cancer (2446)
- T cell receptor signaling pathway (2418)
- Hematopoietic cell lineage (2133)
- Toll-like receptor signaling pathway (2062)
- Colorectal cancer (2023)
- Neurotrophin signaling pathway (1959)
- Melanoma (1921)
- Pancreatic cancer (1863)
- ErbB signaling pathway (1841)
- Bladder cancer (1817)
- Glioma (1764)
- Endometrial cancer (1731)
- Non-small cell lung cancer (1718)
- Regulation of actin cytoskeleton (1712)
- Chronic myeloid leukemia (1683)
- Cell cycle (1639)
- B cell receptor signaling pathway (1597)
- Progesterone-mediated oocyte maturation (1592)
- Jak-STAT signaling pathway (1531)
- Insulin signaling pathway (1457)
- Endocytosis (1407)
- GnRH signaling pathway (1383)
- Fc epsilon RI signaling pathway (1366)
- Apoptosis (1310)
- Natural killer cell mediated cytotoxicity (1295)
- Renal cell carcinoma (1264)
- Acute myeloid leukemia (1244)
- p53 signaling pathway (1185)
- Leukocyte transendothelial migration (1176)
- Wnt signaling pathway (1168)
- Chemokine signaling pathway (1166)
- Small cell lung cancer (1128)
- Purine metabolism (1105)
- VEGF signaling pathway (1089)
- Fc gamma R-mediated phagocytosis (1087)
- Alzheimer's disease (1073)
- Thyroid cancer (1040)
- Gap junction (1030)
- Adherens junction (1012)
- Amyotrophic lateral sclerosis (ALS) (1003)
- Oocyte meiosis (952)
- Ubiquitin mediated proteolysis (932)
- Primary immunodeficiency (930)
- Pyrimidine metabolism (910)
- Huntington's disease (896)
- Melanogenesis (860)
- Complement and coagulation cascades (832)
- Epithelial cell signaling in Helicobacter pylori infection (822)
- Calcium signaling pathway (818)
- Systemic lupus erythematosus (775)
- Adipocytokine signaling pathway (771)
- Type II diabetes mellitus (767)
- mTOR signaling pathway (747)
- NOD-like receptor signaling pathway (740)
- Autoimmune thyroid disease (721)
- Antigen processing and presentation (701)
- Long-term depression (701)
- Axon guidance (683)
- Prion diseases (681)
- Basal cell carcinoma (678)
- Parkinson's disease (678)
- Long-term potentiation (667)
- Tight junction (659)
- Glycolysis / Gluconeogenesis (658)
- Hypertrophic cardiomyopathy (HCM) (634)
- Pathogenic Escherichia coli infection (632)
- Vascular smooth muscle contraction (624)
- Arginine and proline metabolism (623)
- RIG-I-like receptor signaling pathway (614)
- Viral myocarditis (610)
- Lysosome (589)
- Allograft rejection (578)
- Graft-versus-host disease (577)
- ECM-receptor interaction (575)
- TGF-beta signaling pathway (573)
- Type I diabetes mellitus (540)
- Nucleotide excision repair (534)
- Dorso-ventral axis formation (517)
- Cytosolic DNA-sensing pathway (516)
- Dilated cardiomyopathy (504)
- Valine (487)
- PPAR signaling pathway (486)
- Hedgehog signaling pathway (477)
- leucine and isoleucine degradation (476)
- Oxidative phosphorylation (471)
- Proteasome (447)
- Glycerolipid metabolism (416)
- Tryptophan metabolism (409)
- RNA degradation (397)
- Lysine degradation (395)
- Phosphatidylinositol signaling system (394)
- Arrhythmogenic right ventricular cardiomyopathy (ARVC) (385)
- Arachidonic acid metabolism (380)
- Neuroactive ligand-receptor interaction (371)
- Propanoate metabolism (371)
- Pyruvate metabolism (367)
- Drug metabolism - cytochrome P450 (366)
- Metabolism of xenobiotics by cytochrome P450 (362)
- Spliceosome (358)
- One carbon pool by folate (356)
- Inositol phosphate metabolism (353)
- Glutathione metabolism (348)
- Fatty acid metabolism (347)
- Alanine (341)
- aspartate and glutamate metabolism (341)
- Mismatch repair (338)
- Histidine metabolism (331)
- DNA replication (323)
- Tyrosine metabolism (313)
- Notch signaling pathway (308)
- Butanoate metabolism (287)
- Base excision repair (280)
- Glycine (274)
- serine and threonine metabolism (274)
- beta-Alanine metabolism (272)
- Asthma (250)
- Renin-angiotensin system (246)
- Maturity onset diabetes of the young (240)
- ABC transporters (239)
- Drug metabolism - other enzymes (236)
- Vibrio cholerae infection (236)
- Fructose and mannose metabolism (232)
- Cardiac muscle contraction (231)
- Retinol metabolism (218)
- Cysteine and methionine metabolism (215)
- Circadian rhythm - mammal (211)
- Amino sugar and nucleotide sugar metabolism (203)
- Homologous recombination (201)
- Starch and sucrose metabolism (200)
- Nicotinate and nicotinamide metabolism (180)
- Linoleic acid metabolism (174)
- SNARE interactions in vesicular transport (169)
- Citrate cycle (TCA cycle) (165)
- Pentose phosphate pathway (165)
- Regulation of autophagy (157)
- Glycerophospholipid metabolism (145)
- Terpenoid backbone biosynthesis (145)
- RNA polymerase (138)
- Porphyrin and chlorophyll metabolism (137)
- Sphingolipid metabolism (134)
- Nitrogen metabolism (131)
- Aminoacyl-tRNA biosynthesis (130)
- Folate biosynthesis (130)
- Sulfur metabolism (130)
- Ribosome (124)
- Galactose metabolism (118)
- Methane metabolism (116)
- Ascorbate and aldarate metabolism (114)
- Other glycan degradation (113)
- Caffeine metabolism (110)
- Fatty acid elongation in mitochondria (109)
- Primary bile acid biosynthesis (104)
- N-Glycan biosynthesis (103)
- Non-homologous end-joining (93)
- Glyoxylate and dicarboxylate metabolism (91)
- Selenoamino acid metabolism (91)
- Phenylalanine metabolism (81)
- Basal transcription factors (79)
- Cyanoamino acid metabolism (77)
- Synthesis and degradation of ketone bodies (74)
- Androgen and estrogen metabolism (72)
- Olfactory transduction (72)
- Ether lipid metabolism (70)
- Thiamine metabolism (70)
- Limonene and pinene degradation (64)
- Glycosaminoglycan degradation (55)
- Taste transduction (55)
- Pantothenate and CoA biosynthesis (45)
- Biosynthesis of unsaturated fatty acids (40)
- C21-Steroid hormone metabolism (40)
- Riboflavin metabolism (35)
- Fatty acid biosynthesis (33)
- Vitamin B6 metabolism (32)
- Glycosphingolipid biosynthesis - lacto and neolacto series (31)
- Keratan sulfate biosynthesis (30)
- alpha-Linolenic acid metabolism (30)
- Pentose and glucuronate interconversions (29)
- Glycosphingolipid biosynthesis - ganglio series (25)
- Steroid biosynthesis (21)
- Glycosphingolipid biosynthesis - globo series (20)
- leucine and isoleucine biosynthesis (18)
- Taurine and hypotaurine metabolism (16)
- D-Glutamine and D-glutamate metabolism (15)
- Phenylalanine (11)
- tyrosine and tryptophan biosynthesis (11)
- O-Glycan biosynthesis (10)
- Protein export (10)
- Biotin metabolism (5)
- Ubiquinone and other terpenoid-quinone biosynthesis (5)
- Chondroitin sulfate biosynthesis (2)
- Heparan sulfate biosynthesis (2)